The following is a summary of “Effect of dupilumab on exhaled nitric oxide, mucus plugs, and functional respiratory imaging ...

Chime Biologics, a leading global CDMO that enables its partners' success in biologics, today announced its continued ...

Airsupra (PT027), a new asthma rescue treatment developed by AstraZeneca (AZ) and development partner Avillion, has been approved by the US Food and Drug Administration (FDA). A first-in-class ...

GSK's new long-acting drug candidate for severe asthma, depemokimab ... achieve a significant reduction in the annualised rate of moderate or severe exacerbations in the MATINEE trial in chronic ...

Nemluvio has received approval from the European Commission to treat moderate to severe atopic dermatitis and prurigo nodularis in the European Union, Galderma announced in a press release.

The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.

For this reason, ipratropium was not recommended in asthma, except in acute severe asthma management ... The first large study on unselected moderate asthmatics showed that tiotropium was as ...

This week, the European Commission granted approval to Merck’s MRK novel HIF-2α inhibitor, Welireg, for two indications. The ...

Violin teacher Constance Meyer’s chronic hacking cough was driving other people crazy. The mother of a new student figured ...

The study showed that medicine used to help asthma patients for more than 20 years could lessen or prevent acute allergic ...

Researchers Identify Novel Immune Cells That May Worsen Asthma Jan. 15, 2025 — Researchers have made an important discovery in the field of asthma research, identifying a new population of ...

The FDA has granted a fast track designation to rezpegaldesleukin for treating patients aged 12 years and older with moderate ...